Kwame Amponsa-Achiano
Overview
Explore the profile of Kwame Amponsa-Achiano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baral R, Amponsa-Achiano K, Barros I, Cofie P, Dapaah P, Fleming J, et al.
Vaccine
. 2025 Feb;
49:126769.
PMID: 39892111
Introduction: The maternal vaccine landscape is expanding, including the anticipated global rollout of the now approved respiratory syncytial virus maternal vaccine. Integrating maternal immunization (MI) into health systems in low-and...
2.
Nambasa V, Gunter H, Adeyemo M, Bhawaneedin N, Blockman M, Sabblah G, et al.
Drug Saf
. 2025 Jan;
48(3):233-249.
PMID: 39843797
Introduction: The COVID-19 pandemic accelerated new vaccine development. Limited safety data necessitated robust global safety surveillance to accurately identify and promptly communicate potential safety issues. The African Union Smart Safety...
3.
Darko D, Seaneke S, Karikari-Boateng E, Nkansah E, Amponsa-Achiano K, Mohamed N, et al.
Vaccine
. 2024 Oct;
42(26):126460.
PMID: 39447252
Introduction: The development of COVID-19 vaccines during the pandemic occurred with an unprecedented speed, requiring extraordinary post-approval safety monitoring to facilitate ongoing evaluation of their benefit-risk profile. In Ghana, the...
4.
Adjei M, Tweneboah P, Bawa J, Baafi J, Kubio C, Amponsa-Achiano K, et al.
Heliyon
. 2024 Oct;
10(19):e38858.
PMID: 39430453
Introduction: The uptake trend of a new vaccine is unpredictable and may reflect the quality of introduction process and community acceptance. The objective of this study was to conduct a...
5.
Adjei M, Ofori Amoah J, Bonsu G, Okine R, Mohammed N, Amponsa-Achiano K, et al.
Open Forum Infect Dis
. 2024 Oct;
11(10):ofae539.
PMID: 39364172
Background: Ghana introduced a 2-dose schedule rotavirus vaccine, Rotarix, into childhood immunization in 2012 but switched to a 3-dose schedule vaccine, Rotavac, in 2020 on account of programmatic advantages offered...
6.
Adjei M, Tweneboah P, Bonsu G, Baafi J, Amponsa-Achiano K, Asiedu-Bekoe F, et al.
Malar J
. 2024 Sep;
23(1):290.
PMID: 39334244
Background: In May 2019, Ghana piloted the introduction of RTS,S malaria vaccine into routine immunization in 42 districts of seven of the 16 regions. The RTS,S malaria vaccine implementation programme...
7.
Asare A, Sabblah G, Buabeng R, Alhassan Y, Asamoa-Amoakohene A, Amponsa-Achiano K, et al.
PLOS Glob Public Health
. 2024 Sep;
4(9):e0003770.
PMID: 39331603
Vaccines are important public health tools and formed part of the fight against the COVID-19 pandemic. Five COVID-19 vaccines were given Emergency Use Authorization in Ghana and deployed during the...
8.
Muhoza P, Shah M, Amponsa-Achiano K, Gao H, Quaye P, Opare W, et al.
Vaccines (Basel)
. 2024 Jul;
12(7).
PMID: 39066354
Strengthening routine immunization systems to successfully deliver childhood vaccines during the second year of life (2YL) is critical for vaccine-preventable disease control. In Ghana, the 18-month visit provides opportunities to...
9.
Muhoza P, Shah M, Gao H, Amponsa-Achiano K, Quaye P, Opare W, et al.
Vaccines (Basel)
. 2023 Oct;
11(10).
PMID: 37896919
Background: Understanding the drivers of coverage for vaccines offered in the second year of life (2YL) is a critical focus area for Ghana's life course approach to vaccination. This study...
10.
Owusu R, Mvundura M, Nonvignon J, Armah G, Bawa J, Antwi-Agyei K, et al.
PLOS Glob Public Health
. 2023 Aug;
3(8):e0001328.
PMID: 37556413
Ghana introduced rotavirus vaccine (ROTARIX 1-dose presentation) into the routine national immunization program in 2012 and switched to a different product (ROTAVAC 5-dose presentation) in 2020. ROTAVAC has a lower...